KB 002

Drug Profile

KB 002

Alternative Names: KB002

Latest Information Update: 02 Mar 2013

Price : $50

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer KaloBios Pharmaceuticals
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists; Immunosuppressants; Macrophage inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Rheumatoid arthritis

Most Recent Events

  • 27 Feb 2013 Efficacy and safety data from a phase I/II trial in Asthma released by KaloBios Pharmaceuticals
  • 28 Oct 2008 BioWa licenses its Potelligent® technology to KaloBios for improvement of antibody-dependent cellular cytotoxicity
  • 11 Mar 2008 Phase-I/II clinical trials in Asthma in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top